logo-loader
viewFaron Pharmaceuticals Ltd

Faron says interim analysis supports continuation of INFORAAA trial

The ratio of the treatment arm versus placebo was two to one and mortality was assessed for a period of 30 days after surgery.

Medical professional checking up on patient
Interim analysis supports continuation of the study

Faron Pharmaceuticals Oy (LON:FARN) is mulling its next steps after receiving interim results from the INFORAAA trial of its interferon-beta drug Traumakine.

The company has announced the interim results from the Phase II INFORAAA study, which examined the effect of Traumakine on mortality and pharmacodynamic (the biochemical and physiological effects of drugs) biomarkers of surgically-operated ruptured abdominal aorta aneurysm patients.

Faron said analysis of the interim results supported the continuation of the study.

READ Faron getting to the bottom of the Traumakine conundrum

Traumakine treatment during the INFORAAA trial was identical to the INTEREST trial (a phase III clinical trial on patients with acute respiratory distress syndrome), Faron said.

A total of 35 patients were included in the interim read-out, 25 of which were treated with Traumakine and 10 of which received a placebo.

Faron said the responses from the MxA and CD73 biological markers (biomarkers) indicated a good interferon response. Unexpectedly, at the same time, corticosterone was recorded both in the active (28%) and placebo (30%) treatment arm.

The measurement of CD73 serum concentrations indicated that this concomitant corticosteroid use negated a CD73 response, as observed earlier in all three previous studies - two independent phase III and the company's own YODA study that was instigated to find out why Traumakine did not perform as expected in the INTEREST trial.

Patients without Traumakine-induced CD73 values were more likely to die than those with induction, Faron said. The corticosteroid-treated patients from statistical analysis reduced group sizes and made statistical mortality analysis meaningless, but a trend toward reduction of mortality was seen in the Traumakine-treated patients who did not receive corticosteroids.

Mortality in various groups varied from 15-20%, except in those patients without induced CD73 concentrations - mortality in that group was high with six out of seven not surviving.

The company said it would evaluate the interim results in conjunction with previously announced data from the YODA trial and post-hoc INTEREST data to finalise its plans for future Traumakine development and will make further announcements in due course.

"The INFORAAA interim data is very important to us as it again shows the protective effects of CD73 activation without the presence of steroids,” said Dr Markku Jalkanen, the chief executive officer of Faron.

“It is still too early to estimate the efficacy of Traumakine in this setting because of the limited number of evaluable patients without concomitant steroids; however, the interim analysis supports the continuation of the study according to current powering,” he added.

“It was disappointing to learn about this magnitude of steroid use in this patient population as RAAA [ruptured abdominal aorta aneurysm patients] is considered as a traumatic condition and to have only limited inflammatory impact on disease development," the CEO concluded.

Quick facts: Faron Pharmaceuticals Ltd

Price: 170 GBX

AIM:FARN
Market: AIM
Market Cap: £73.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

on 16/10/19

RNS

Second Price Monitoring Extn

3 days, 3 hours ago

Price Monitoring Extension

3 days, 3 hours ago

Registration of Shares

5 days, 22 hours ago

Second Price Monitoring Extn

1 week, 6 days ago

Price Monitoring Extension

1 week, 6 days ago

Second Price Monitoring Extn

1 week, 6 days ago

3 min read